Recent federal announcements serve as reminders that in the US policy continues to outpace science when it comes to cannabis.

The federal government cautions that the drug can affect brain development in both teens and fetuses.

A Novartis subsidiary is partnering with a Canadian cannabis company to sell medical marijuana worldwide.

The country is the second in Africa to permit cannabis cultivation, but months after approval there’s been little uptake by farmers and no scientific proposals.

The coming legalization of recreational marijuana is already increasing funding for studies, but regulations on such research have been slow to change.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Around 40 percent of children with an uncommon disorder had 50 percent fewer seizures while taking the marijuana derivative.

In young mice, THC had the opposite effect.

US scientists continue to have a hard time getting funding to study the health impacts of the drug. But cannabis research in Canada—where medical marijuana is legal nationwide—is different story.